325 related articles for article (PubMed ID: 32522798)
1. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
[TBL] [Abstract][Full Text] [Related]
2. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
van de Beek M; Ooms FAH; Ebenau JL; Barkhof F; Scheltens P; Teunissen CE; van Harten AC; van der Flier WM; Lemstra AW
Neurology; 2022 Mar; 98(12):e1262-e1272. PubMed ID: 35074893
[TBL] [Abstract][Full Text] [Related]
3. Applying the ATN scheme in a memory clinic population: The ABIDE project.
Altomare D; de Wilde A; Ossenkoppele R; Pelkmans W; Bouwman F; Groot C; van Maurik I; Zwan M; Yaqub M; Barkhof F; van Berckel BN; Teunissen CE; Frisoni GB; Scheltens P; van der Flier WM
Neurology; 2019 Oct; 93(17):e1635-e1646. PubMed ID: 31597710
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal change in ATN biomarkers in cognitively normal individuals.
Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM
Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616
[TBL] [Abstract][Full Text] [Related]
5. Exploring the ATN classification system using brain morphology.
Heinzinger N; Maass A; Berron D; Yakupov R; Peters O; Fiebach J; Villringer K; Preis L; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Bartels C; Jessen F; Maier F; Glanz W; Buerger K; Janowitz D; Perneczky R; Rauchmann BS; Teipel S; Killimann I; Göerß D; Laske C; Munk MH; Spottke A; Roy N; Heneka MT; Brosseron F; Dobisch L; Ewers M; Dechent P; Haynes JD; Scheffler K; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Düzel E; Ziegler G;
Alzheimers Res Ther; 2023 Mar; 15(1):50. PubMed ID: 36915139
[TBL] [Abstract][Full Text] [Related]
6. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
[TBL] [Abstract][Full Text] [Related]
7. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
8. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
9. β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
Rosenberg A; Öhlund-Wistbacka U; Hall A; Bonnard A; Hagman G; Rydén M; Thunborg C; Wiggenraad F; Sandebring-Matton A; Solomon A; Kivipelto M
Neurology; 2022 Nov; 99(19):e2102-e2113. PubMed ID: 36130840
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
[TBL] [Abstract][Full Text] [Related]
13. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
14. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of imaging-based ATN profiles in a memory clinic cohort.
Peretti DE; Ribaldi F; Scheffler M; Chicherio C; Frisoni GB; Garibotto V
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3313-3323. PubMed ID: 37358619
[TBL] [Abstract][Full Text] [Related]
18. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
19. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]